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Aims: To investigate age-related persistence with bisphosphonates (BIS) in women with breast cancer
(BC) and bone metastases.
Methods: We included a dataset of 1541 patients diagnosed with BC and bone metastases and initially
treated with BIS between 1994 and 2013. The primary outcome measure was the age-related rate of BIS
discontinuation within 12 months after treatment initiation. Therapy discontinuation was deﬁned as a
period of at least 90 days without treatment. A multivariate Cox regression model was created to de-
termine the inﬂuence of age on the risk of discontinuation. Health insurance coverage (private/statutory),
type of care (gynecological/general), region (West/East Germany), depression, chemotherapy, hormone
therapy, pain medication, antidepressants, and the number of co-medications were included as covari-
ates.
Results: The mean ages in the group of women o70 and that of women Z70 years of age were 55.7 (SD:
9.8) and 76.7 (SD: 5.1) years respectively. Within 12 months after treatment initiation, 44.3% of women
o70 and 34.8% of women Z70 had terminated treatment (p-valueo0.001). Patients aged Z70 were at
a lower risk of treatment discontinuation than patients o70 (HR¼0.78, 95% CI: 0.67–0.91). Furthermore,
treatment in gynecological practices, chemotherapy, hormone therapy, pain medication, and number of
co-medications decreased the risk of discontinuation. By contrast, residing in West Germany and private
health insurance coverage increased discontinuation risk.
Conclusions: Women with metastatic BC aged Z70 are at a lower risk of BIS treatment discontinuation
than younger women.
& 2016 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Breast cancer (BC) is the most common cancer in women, with
approximately 1.7 million new diagnoses in 2012. This ﬁgure re-
presents about 25% of all new cancer cases in women and 12% of
those in the general population [1]. Today, the median age at di-
agnosis is around 60 years and, since 20% of the global population
will be aged 465 years by 2030, the number of women diagnosed
with BC in this age group is likely to increase in the future.
In womenwith BC, bone is the most common site of metastases
[2–5]. Since bone lesions cause signiﬁcant damage to the bone
microstructure, patients with metastatic BC are at a high risk of
skeletal-related events (SREs), such as bone pain, hypercalcemia,
bone fracture, or spinal cord compression, which could potentiallyGmbH. This is an open access art
dence Solutions, IMS HEALTH
60598 Frankfurt am Main,
stev).affect quality of life and life expectancy [6,7]. There are various
bone metastasis treatments, depending on the number and the
site of the lesions (i.e. radiotherapy, chemotherapy, or orthopedic
intervention). Complementing these treatments is the role of
bone-targeted agents such as bisphosphonates (BIS) [8,9]. Al-
though no consensus has yet been reached on the optimal dura-
tion of BIS therapy, BIS use is generally recommended for a period
of several years.
One signiﬁcant problem associated with chronic conditions is the
lack of treatment persistence and compliance. It has been demon-
strated that around 50% of patients suffering from such conditions
discontinue their therapy early [10]. In the case of BC, older women
are known to be at a higher risk of treatment discontinuation than
younger women [11]. This has also been demonstrated in several
studies concerning the adjuvant treatment of women with BC.
Consequently, lower persistence in older women with BC and bone
metastases treated with BIS would lead to a reduced clinical beneﬁt.
Recently, Hadji and colleagues demonstrated that persistence
with intravenous and oral BIS is unexpectedly low and ought to beicle under the CC BY-NC-ND license
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with intravenous and oral breast cancer-related BIS treatment in
younger (o70) and older (Z70) women with BC treated in gy-
necological practices in Germany.Table 1
Baseline characteristics of womenwith breast cancer and bone metastasis receiving
bisphosphonate treatment: IMS HEALTH Disease Analyzer, Germany.
Variables o70 years 4¼70 years p-Value
N 1133 408
Age (years) 55.7 (9.8) 76.7 (5.1) o0.001
Gynecologist treatment (%) 50.1 40.4 o0.001
Private health insurance coverage (%) 14.1 9.0 0.004
Region (West Germany) (%) 86.4 81.8 0.017
Intravenous bisphosphonates (%) 73.2 74.5 0.591
Co-diagnosisa (%):
Depression 28.3 30.0 0.499
Co-treatmentb (%):
Chemotherapy 34.5 19.9 o0.001
Hormone therapy 70.4 73.7 0.164
Antidepressants 23.4 22.4 0.669
Pain medication 58.0 62.0 0.128
Number of different drugs taken per day 2.9 (2.0) 3.2 (2.2) 0.019
Data are means (SD) or proportions (%).
a Diagnosis prior to index date or during bisphosphonate treatment.
b Prescriptions prior to index date or during bisphosphonate treatment.2. Methods
2.1. Database
The Disease Analyzer database (IMS HEALTH) compiles drug
prescriptions, diagnoses, basic medical and demographic data ob-
tained directly and in anonymous format from computer systems
used in the practices of general practitioners [13]. Diagnoses (ICD-
10), prescriptions (Anatomical Therapeutic Chemical (ATC) Classiﬁ-
cation System) and the quality of reported data have been mon-
itored by IMS based on a number of criteria (e.g., completeness of
documentation, linkage between diagnoses and prescriptions).
In Germany, the sampling methods used for the selection of
physicians’ practices were appropriate to obtain a representative
database of general and gynecological practices [13]. Prescription
statistics for several drugs were very similar to data available from
pharmaceutical prescription reports [13]. The age groups for given
diagnoses in Disease Analyzer also complied well with those in
corresponding disease registries [13]. Finally, the Disease Analyzer
database has already been used to perform studies on cancer, and
more particularly BC, in Germany [1,14–16].
2.2. Study population
Overall, the database included 2067 general practices and 397
gynecological practices reporting to IMS HEALTH on a continuous
basis during the study period. First-time cancer-related BIS pre-
scriptions (ATC: M03B4) from January 1994 until December 2013
in subjects diagnosed with bone metastases (ICD 10: C795) fol-
lowing breast cancer diagnosis (ICD 10: C50) were deﬁned as the
index dates; the latest follow-up date was identiﬁed as April 2014.
Patients with a follow-up time of less than 365 days prior to the
index date were excluded. This exclusion was necessary to ensure
correct identiﬁcation of treatment initiation. Further inclusion
criteria comprised the following: age of over 18 years at the index
date and no diagnosis of other tumors in the time between ﬁrst BC
diagnosis and ﬁrst bone metastasis diagnosis.
A total of 1541 patients were available for persistence analysis.
These patients were treated in 185 gynecological and 515 general
practices.
Individuals were classiﬁed into two different groups: one in-
cluding women under 70 years of age and one including women
70 years of age or over.
2.3. Study outcome
The main outcome measure was BIS treatment discontinuation
rate within one year after the index date. Treatment discontinua-
tion of a speciﬁc BIS therapy was deﬁned as a period of 90 days
devoid of this or an alternative BIS therapy within that time frame.
Persistence is deﬁned as the time from the beginning of therapy to
therapy discontinuation.
A longitudinal dataset of medication supply was established for
each individual patient and non-persistence with one of the study
drugs (i.e. zoledronate, ibandronate, clodronate and pamidronate)
was calculated. As part of this process, the number of days of drug
supply was calculated on the basis of the quantity and dosage in-
formation associated with each prescription record. All patients
were monitored for a duration of at least three months to one year
from their index date in order to identify treatment discontinuation.In addition, the share of patients switching treatment was
calculated as patients commencing an alternative BIS therapy after
the ﬁrst day of discontinuation of the initial treatment. Patients
restarting the initial treatment or starting another BIS therapy
after 90 days without treatment were still classiﬁed as non-per-
sistent, along with patients who discontinued their initial therapy
and received no further BIS treatment. Patients restarting the in-
itial therapy or starting another BIS therapy within 90 days were
counted as persistent. Women who died during the study time
frame were excluded from the analyses.
2.4. Covariates
Demographic data included age, health insurance coverage
(private or statutory), gynecologist care, and practice region (East
versus West Germany). Co-diagnoses of depression were de-
termined based on primary care diagnoses (ICD-10 codes: F32,
F33). Furthermore, the pre- or co-treatment was deﬁned based on
Anatomical Therapeutic Chemical Classiﬁcation (ATC) for che-
motherapy (L01, L02), endocrine treatment (tamoxifen or ar-
omatase inhibitors), pain medication (ATC: N02A, N02B, M01A),
and antidepressants (ATC: N06A). Finally, the number of co-med-
ications was deﬁned as the maximum number of different drugs a
patient was prescribed to take in a single day.
2.5. Statistical analysis
Kaplan-Meier analyses were performed to examine treatment
persistence in the two different age groups. A Cox proportional
hazards regression model was used to estimate the relationship
between non-persistence and age as well as the other demo-
graphical/clinical variables described previously. A p-value of
o0.05 was considered statistically signiﬁcant. Analyses were car-
ried out using SAS version 9.3.3. Results
3.1. Patient characteristics
Patient characteristics are displayed in Table 1. A total of 1541
women with BC and bone metastases were included in this study,
of which 1133 were o70 (mean age¼55.7, SD¼9.8) and 408 Z70
(mean age¼76.7 and SD¼5.1). The proportion of patients with
private health insurance coverage, residing in West Germany and
Fig. 1. Kaplan–Meier curves for persistence of women with breast cancer and bone
metastases.
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women agedo70 than in the group of patients aged Z70 (14.1%
versus 9.0%, 86.4% versus 81.8% and 50.1% versus 40.4%; all p-va-
lues lower than 0.017). By contrast, the proportion of women re-
ceiving intravenous BIS as initial treatment and exhibiting de-
mentia did not differ signiﬁcantly between the two age groups
(73.2% versus 74.5%, p-value¼0.591; and 28.3% versus 30.0%, p-
value¼0.499). Finally, the use of chemotherapy was more com-
mon in the younger age group than in the older one (34.5% versus
19.9%, p-value o0.001), whereas the use of endocrine treatment,
antidepressants, and pain medications did not differ between the
two groups. The number of drugs being taken was signiﬁcantly
higher in women aged Z70 than in women o70 (3.2 versus 2.9,
p-value¼0.019).
3.2. BIS treatment persistence
Fig. 1 displays Kaplan-Meier curves for the time to dis-
continuation of BIS treatment in women with BC and bone me-
tastases as a function of age (o70 versus 4¼70). Within 12
months after treatment initiation, 44.3% of women o70 and 34.8%
of women aged Z70 had discontinued treatment (Log-Rank p-
valueo0.001). The results of the Cox regression model are shown
in Table 2. Patients aged Z70 were at a lower risk of BIS treatment
discontinuation than patients o70 (HR¼0.78, 95% CI: 0.67–0.91
and p-value¼0.001). While residing in West Germany and having
private health insurance coverage increased the chances of dis-
ruption (HR¼2.01, 95% CI: 1.60–2.52, p-valueo0.0001, and
HR¼1.32, 95% CI: 1.07–1.62, p-value¼0.009), gynecological care,Table 2
Association of bisphosphonate treatment discontinuation within 1 year with de-
ﬁned variables: Cox regression analyses.
Outcome variables Hazard ratioa (95%CI) p-Value
Age 4¼70 versus o70 0.78 (0.67–0.91) 0.001
West Germany versus East Germany 2.01 (1.60–2.52) o0.001
Private health versus statutory health in-
surance coverage
1.32 (1.07–1.62) 0.009
Chemotherapy 0.74 (0.63–0.87) o0.001
Hormone therapy 0.68 (0.57–0.80) o0.001
Pain medication 0.70 (0.59–0.82) o0.001
Number of different drugs taken per day 0.83 (0.78–0.89) o0.001
Gynecologist treatment versus GP treatment 0.83 (0.71–0.98) 0.024
Intravenous versus oral bisphosphonates 1.00 (0.85–1.17) 0.997
Depression 0.97 (0.82–1.15) 0.745
Antidepressants 0.94 (0.77–1.15) 0.550
a Discontinuation of therapy adjusted for age, region (west Germany), urban
residency, gynecologist care, health insurance coverage (private), and all variables
in the model.chemotherapy, endocrine treatment, pain medications, and the
number of drugs taken per day decreased the risk of treatment
discontinuation (HR¼0.83, 95% CI: 0.71-0.98, HR¼0.74, 95% CI:
0.63–0.87; HR¼0.68, 95% CI: 0.57–0.80; HR¼0.70, 95% CI: 0.59–
0.82; and HR¼0.83, 95% CI: 0.78–0.89, respectively; all p-values
lower than 0024). By contrast, BIS type (intravenous/oral), de-
pression, and the use of antidepressants did not signiﬁcantly im-
pact treatment persistence.4. Discussion
In our study, we were able to demonstrate that women aged
Z70 discontinued their BIS treatment less frequently than women
aged o70 years during the one-year follow-up period. In addition,
we showed that residing in West Germany and having private
health insurance coverage increased the risk of therapy dis-
continuation, whereas age, gynecological care, chemotherapy,
endocrine treatment, pain medications, and the number of drugs
taken per day decreased this risk.
BC is a cancer that is frequently associated with metastases,
particularly bone metastases. These malignant bone diseases have
a negative impact on the balance between bone formation and
resorption [12]. Although BIS are one component of the standard
recommended treatment for women with BC and bone metas-
tases, both their safety and their efﬁcacy proﬁle need to be taken
into account. Thus, therapy persistence is of the utmost im-
portance in achieving the optimal outcome as observed in RCTs.
Nonetheless, treatment discontinuation rates are high, reaching
50% in patients with chronic diseases. One of the major factors
impacting treatment discontinuation in women with BC is age
[11,17]. On the basis of their study in 2003 including 2378 post-
menopausal women with BC from New Jersey, Partridge et al.
demonstrated that both patients aged o45 and 485 were at a
higher risk of therapy discontinuation [18]. He and his colleagues
recently corroborated these results in 3395 women with BC from
Sweden, since women o40 and 465 had a higher likelihood of
treatment discontinuation [19]. There are several hypotheses that
may explain this non-linear, complex relationship between ther-
apy persistence and age. It is known that older women are more
commonly affected by BC than younger women and thus tend to
adjust better to this chronic disease [20–22]. Since the prognosis
for younger women with BC is worse on average than that for
older women with the disease, their poor compliance and per-
sistence is of particular concern [23]. By contrast, patients aged
480 usually suffer from multiple diseases and insufﬁcient social/
familial support, leading to a decrease in treatment compliance
and persistence [18,24]. Interestingly, several studies have also
demonstrated that persistence with BIS therapy increases with age
[25,26]. In their 2005 study comprising 2124 postmenopausal
women treated with alendronate, etidronate, or risedronate,
Penning-van Beest and colleagues found that BIS persistence was
higher in patients aged between 65 and 69 and between 70 and 74
than in patients aged between 55 and 59 [25]. Three years later,
Gallagher et al. showed in 44,531 patients treated with oral BIS
that patients aged 460 exhibit higher compliance and persistence
rates than patients o60 [26]. Therefore, our ﬁndings are in line
with these reports and demonstrate that age positively impacts
BIS treatment persistence in women with BC and bone metastases.
Our study also showed that the risk of treatment discontinua-
tion is lower in patients treated in gynecological practices than in
those receiving treatment in general practices. In this context, it is
worth mentioning that in Germany, gynecologists are customarily
responsible for the treatment and management of womenwith BC.
Interestingly, chemotherapy, endocrine treatment, pain medica-
tions, and the number of drugs served in preventing
L. Jacob et al. / Journal of Bone Oncology 5 (2016) 63–6666discontinuation. This result is not in line with those of He et al.,
who recently reported that the number of medications decreased
persistence with endocrine treatment in BC patients [19]. None-
theless, there are two important differences in our study. We did
not analyze persistence with endocrine treatment, rather, we fo-
cused on BIS therapy and also only included women with BC and
bone metastases. It is possible that the follow-up of patients with
high numbers of treatments was more speciﬁc than the follow-up
of patients with lower numbers of medications.
Residing in West Germany also decreased BIS persistence. In
2015, Jacob et al. demonstrated in 4,915 BC women that the
treatment discontinuation rate is higher in West Germany than in
East Germany [1]. Finally, our study returned one outcome that
requires careful discussion: we found that private health insurance
increased the risk of treatment discontinuation. This ﬁnding may
cause confusion since women with private health insurance cov-
erage are usually wealthier than those with statutory insurance
coverage. Although patients who subscribe to a private health
insurance plan may beneﬁt from better medical treatment and
management, one must consider the fact that these patients may
display risk factors for therapy disruption not present or less
present in other patients.
This study was subject to several limitations, one of which is
that the population included was not selected speciﬁcally by age
and therefore the proportion of elderly women was relatively
small. Consequently, we were only able to differentiate between
two different age groups (o70 and 4¼70). Nevertheless, we
believe that as the age range in our study population is in con-
cordance with the age range of the majority of people with BC
among the general population, it therefore does not introduce a
selection bias. In addition, the database did not include any valid
information on TNM classiﬁcation. Furthermore, no detailed doc-
umentation of treatment side effects was available. Data on so-
cioeconomic status and lifestyle-related risk factors were also
unavailable.
Women aged Z70 with BC and bone metastases were at a
lower risk of BIS treatment discontinuation than women o70.
Further studies are required to gain a better understanding of the
non-linear, complex relationship between age and treatment
persistence.References
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